Unlocking the Full Potential of Combined Capabilities
SPONSORED CONTENT: From AI-driven secondary packaging to enhanced business continuity, Timothy Compton outlines how Alcami is merging its legacy manufacturing excellence with new digital innovations to serve global markets.
The global pharmaceutical landscape is increasingly defined by the need for speed and regulatory fluidity across multiple jurisdictions. For CDMOs, the ability to offer a unified end-to-end solution, taking sponsors from drug product manufacturing to final commercial packaging and release, has become a significant competitive differentiator. By removing the friction often found at the interface of manufacturing and secondary packaging, providers can significantly de-risk the path to market for complex therapies.
Alcami’s recent acquisition of the Netherlands-based contract packaging organization, Tjoapack (1), represents a pivotal shift by the company to remove this friction. This move not only establishes Alcami’s first physical foothold in Europe but also integrates specialized qualified person (QP) release services and automated secondary packaging into their core offering. In this interview, Timothy Compton, Chief Strategy Officer, Alcami, explores the strategic drivers behind the deal and how a centralized transatlantic footprint aims to solve the fragmented release processes that often plague global drug sponsors.
Multiple Strategic Drivers
Q. Alcami has recently announced that it is acquiring contract packaging organization, Tjoapack, could you provide some insights into what the primary strategic driver was for this acquisition?
A. There are multiple strategic drivers of the Tjoapack acquisition. The first being a trans-Atlantic footprint in Europe to further access global markets. The second being expansion of our packaging and labelling services beyond the legacy Alcami capabilities in Wilmington, NC. This not only provides redundancy for business continuity in the U.S. but also expands our scale and ability to support larger clinical and commercial packaging programs.
Advantageous European Presence
Q. This deal also marks the first expansion for Alcami into Europe. How will the Etten-Leur site in the Netherlands serve as a strategic anchor for U.S.-based sponsors?
A. Our U.S.-based drug product manufacturing clients have already expressed interest in support from the Netherlands site. Whether it’s support for Qualified Person (QP) release or commercial packaging of their product for rest-of-world. The acquisition was promptly validated by our clients, who recognized its advantages immediately upon the announcement.
Q. Can you explain the regulatory and timeline advantages European QP release provides to global sponsors who are often slowed down by fragmented release processes?
A. Our drug product manufacturing clients have continually asked if we have QP services and that answer is now a resounding, yes. The Tjoapack team has a robust process to assist customers with Annex 16 GMP QP release tasks, covering qualification, documentation review, necessary quality agreements, and operational setup.
A Period of Alignment
Q. Tjoapack has been a vocal proponent of using AI and automation in secondary packaging. Are there plans to integrate these digital innovations across Alcami’s broader manufacturing network?
A. Integration activities have just recently commenced at both the U.S. and Netherlands sites. We will systematically evaluate best practices and implement those that align with our goals. Bringing together these organizations offers valuable new perspectives from each location, enabling us to enhance efficiency and deliver greater value to our clients.
Prioritizing a Seamless Integration
Q. With this first European foothold established, should the industry expect further geographic expansions, or is the immediate focus now on deepening the technical integration of these two global teams?
A. Our priority is to integrate seamlessly for clients and our expanded team while maintaining business continuity across sites and services. Ultimately, clients will assess our integration's success, and the market will determine its value.
Reference
Alcami. Alcami Completes Acquisition of Tjoapack. Press Release, May 5, 2026.
About the Interviewee
Timothy Compton is the Chief Strategy Officer for Alcami. Bringing three-decades of industry experience with an extensive background in building and leading commercial operations. Before joining Alcami, Compton was the Chief Commercial Officer at Avid Bioservices, Inc., a contract large molecule bulk drug substance development and manufacturer. Prior to Avid, Timothy was the Vice President of Sales and Marketing at Avista Pharma, a private equity-backed global CDMO acquired by Cambrex.
Timothy also served in numerous executive leadership roles at AAIPharma Services Corporation, a predecessor company to Alcami. During the first 10-years of his career, he supported small innovator biotech/pharma start-up companies, advancing pharmaceuticals from discovery to the clinic. Timothy holds a B.S. in Microbiology from Washington State University and is an active-duty veteran of the U.S. Army.
Image Credit: © tang90246 - stock.adobe.com